SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Potter, A., Debrah, O., Ashun, J. and Blanchet, K. (2013) Eye Health Systems Assessment (EHSA): Ghana Country Report.

has been cited by the following article:

  • TITLE: Cost-Utility of Prostaglandin Analogues Compared to Beta Blockers as First-Line Medication for Treating Primary Open Angle Glaucoma in Ghana

    AUTHORS: Enock Takyi

    KEYWORDS: Glaucoma, Ghana, Prostaglandin Analogue, Beta Blocker, ICER, Cost-Effectiveness

    JOURNAL NAME: Modern Economy, Vol.8 No.11, November 6, 2017

    ABSTRACT: Ghana ranks among the countries most affected by glaucoma in the world. It is estimated that 700,000 people in Ghana are affected by glaucoma, out of which 60,000 people are already blind. In recent years, there has been a growing concern that anti-glaucoma medications listed on the country’s health insurance medicines list are not adequate to manage the disease. This has led to calls from different stakeholders for prostaglandin analogues to be added to the medicines list. However, the cost-effectiveness of this medication is yet to be established. The objective of this study, therefore, was to establish the cost-effectiveness of prostaglandin analogues as first-line medication for treating primary open angle glaucoma in Ghana. A Markov Model was constructed to assess the life-time cost-effectiveness of treating a hypothetical cohort of one thousand 55-year-old POAG patients with prostaglandin analogues compared to beta blockers. The effect of parameter uncertainty on cost-effectiveness was explored through one-way, two-way, and probabilistic sensitivity analyses. Compared to beta blockers, prostaglandin analogues resulted in an incremental cost-effectiveness ratio (ICER) of USD 11,600; based on an estimated incremental gain of 105 quality-adjusted life years (QALYs), at an additional cost of USD 1,222,400. The ICER was not sensitive to the age of the cohort, the cost of prostaglandin analogues, or the probability of developing asthma. However, the ICER was sensitive to the age of the cohort and the cost of prostaglandin analogues when varied simultaneously. Given the existing evidence, prostaglandin analogue is not a cost-effective alternative to beta blockers as a first-line treatment for POAG in Ghana. The study, however, shows that further research to reduce decision uncertainty would be necessary if expected cost of research does not exceed USD 131 billion.